Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib roll-over long-term safety study
2026-525890-38-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS) and breast cancer, sponsored by Novartis. Primary endpoint: Frequency and severity of adverse events and serious adverse events. Planned start Oct 2026; status: authorised.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)breast cancer
Beyond the preview
Go deeper on 2026-525890-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525890-38-00.